.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Deloitte
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Citi
Argus Health
Teva

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,271,975

« Back to Dashboard

Which drugs does patent 9,271,975 protect, and when does it expire?


Patent 9,271,975 protects AKYNZEO and is included in one NDA.

This patent has fifty patent family members in thirty-six countries.

Summary for Patent: 9,271,975

Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH)
Application Number:14/069,970
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes9,271,975► Subscribe PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,271,975

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,623,826Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
9,186,357Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
8,951,969Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,271,975

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2012005347► Subscribe
Morocco33810► Subscribe
Cuba24048► Subscribe
Cyprus1115471► Subscribe
Denmark2361090► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Fish and Richardson
McKesson
Cantor Fitzgerald
Healthtrust
Julphar
Cerilliant
Dow
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot